Indrayani Biotech Limited has revised the timeline for its partly paid-up rights issue, extending the subscription window by one month. The Rights Issue Committee approved the changes at its meeting on May 25, 2026, shifting the issue period to allow shareholders more time to participate.

The rights issue was originally scheduled to be open from May 27, 2026 to June 25, 2026. Under the revised schedule, the issue will now open on June 25, 2026 and close on July 24, 2026. Consequently, the last date for on-market renunciation of rights shares has been moved from June 16, 2026 to July 20, 2026.

Revised Rights Issue Schedule

The company confirmed that apart from the adjustments to the opening, closing, and renunciation dates, there are no other changes to the issue documents. The revised Letter of Offer (LOF), Abridged Letter of Offer (ALOF), Composite Application Form (CAF), and Entitlement Letter will be available on the BSE website and the company's official website.

Ramya Ravi, Company Secretary and Compliance Officer, signed the disclosure regarding the schedule revision.

Indrayani Biotech Limited has informed stock exchanges about receiving a significant Income Tax assessment order and its subsequent legal response. The company disclosed this development under SEBI regulations on April 25, 2026.

Income Tax Assessment Details

The company received an Assessment Order dated March 26, 2025, from the Income Tax Department raising a demand of ₹13.90 crores. This assessment pertains to Assessment Year 2023-24 and was passed under Section 143(3) of the Income Tax Act, 1961.

Legal Response and Appeal

Following established procedures under the Income Tax Act, 1961, Indrayani Biotech has formally contested the demand by filing an appeal before the Income Tax Appellate Tribunal (ITAT). The company is currently awaiting the date for the first hearing in this matter.

The opposing party in this litigation is the Income Tax Department, and the case status remains sub-judice with proceedings pending before ITAT.

Financial Impact Assessment

Based on advice from its legal advisors, the company has assessed that:

• The demand is not expected to have any material adverse impact on financial operations
• No immediate cash outflow is anticipated as the matter is under legal proceedings
• The total potential financial implication stands at ₹13.90 crores plus applicable interest

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided detailed information as per SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, covering all aspects of the litigation including the quantum of claims, current status, and management's assessment of the situation.